INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD)
© 2026 IJNRD | Volume 11, Issue 10, October 2026 | ISSN: 2456-4184 | IJNRD.ORG

Design and Synthesis of Novel COX-2 Selective Inhibitor Candidates Using Scaffold-Based Synthesis

(**[1]Shruti Sawarkar, [2]Vaishnav Sawarkar, [3]Ashlesha Selkar , [4]Sanjana Soge, [5]Ashwini Khodatkar)**
Department of Pharmaceutical Chemistry
Agnihotri Institute of Pharmacy, (Shindi meghe), bapuji wadi ramnagar, Wardha, Maharashtra-442001
[Email ID: vaishnavsawarkar820@gmail.com]

Abstract
Cyclooxygenase-2 (COX-2) is an inducible enzyme involved in the conversion of arachidonic acid into prostaglandins that participate in inflammation, pain and fever. Conventional non-steroidal antiinflammatory drugs (NSAIDs) inhibit both COX-1 and COX-2 and may produce gastrointestinal adverse
effects because of COX-1 inhibition. Therefore, selective inhibition of COX-2 has become an important strategy in the development of anti-inflammatory agents. However, cardiovascular safety concerns associated with some selective COX-2 inhibitors have encouraged the search for new chemical scaffolds with improved potency, selectivity and safety.[1,2]
Scaffold-based drug design provides an important approach for discovering novel COX-2 inhibitors by modifying established pharmacophores and introducing new heterocyclic and aromatic frameworks. Diaryl heterocycles, pyrazoles, indoles, pyridazines, triazoles, xanthones and other heterocyclic scaffolds have been investigated for COX-2 inhibition. Recent studies have demonstrated that appropriate substitution, hydrogen-bonding groups and hydrophobic interactions can significantly influence COX-2 selectivity.[3,8] This review summarizes the biological importance of COX-2, structural requirements for selective inhibition, important scaffolds, structure–activity relationships (SAR), synthetic approaches and recent developments in the design of novel COX-2 selective inhibitor candidates.

Keywords: COX-2, selective inhibitor, scaffold-based design, NSAIDs, heterocyclic compounds, SAR,synthesis, molecular docking.

1.Introduction

Inflammation is a protective biological response to tissue injury or harmful stimuli. Prostaglandins are important mediators involved in inflammation, pain and fever. Cyclooxygenase (COX), also known as prostaglandin-endo peroxide synthase, catalyses important steps in prostaglandin biosynthesis. Two major isoforms, COX-1 and COX-2, are involved in this pathway. COX-1 is generally expressed constitutively and contributes to physiological functions, whereas COX-2 is strongly induced during inflammatory responses.[1,2]
NSAIDs such as ibuprofen, diclofenac and indomethacin exert their effects mainly through inhibition of COX enzymes. However, inhibition of COX-1 can contribute to gastrointestinal toxicity. This led to the development of selective COX-2 inhibitors, commonly called coxibs, with the objective of retaining antiinflammatory activity while reducing gastrointestinal adverse effects.[1,3]
Celecoxib and several other selective COX-2 inhibitors demonstrated the potential of this approach. However, cardiovascular concerns associated with some COX-2 inhibitors, including rofecoxib, demonstrated that COX-2 selectivity alone does not guarantee an ideal safety profile. Consequently, researchers continue to investigate new molecular scaffolds and optimized structures.[1,4]

4. Applications

- Drug discovery and development.
- Development of new lead compounds.
- Structure–activity relationship (SAR) studies.
- Optimization of biological activity and selectivity.

5. Advantages

- Helps generate a variety of related compounds.
- Supports systematic drug development.
- Can reduce the time required to explore chemical derivatives.

- Rapid drug discovery: Helps develop new drug candidates in less time.
- Structural diversity: Produces a variety of compounds from a common molecular scaffold.
- Improved biological activity: Helps identify compounds with better pharmacological effects.
- Cost-effective: Can reduce the time and resources required for drug development.

2. COX-2 as a Drug Target

COX-2 is an important target for the treatment of inflammatory disorders because its expression increases in response to inflammatory stimuli, cytokines and growth factors. Inhibition of COX-2 reduces the formation of pro-inflammatory prostaglandins. [2,4]

The active-site architecture of COX-2 differs from that of COX-1 in ways that allow appropriately designed molecules to achieve preferential binding. Medicinal-chemistry studies have therefore focused on molecular size, shape, lipophilicity, electronic properties, hydrogen-bonding capacity and positioning of substituents.[5]

A major strategy in COX-2 inhibitor development is the incorporation of a polar/sulfonamide or sulfonecontaining group together with hydrophobic aromatic or heteroaromatic regions. Such structural features can help compounds interact favourably with the COX-2 binding site. [3,5]

3. Need for Novel COX-2 Selective Inhibitors

Although selective COX-2 inhibition can provide an improved gastrointestinal profile compared with nonselective NSAIDs, cardiovascular safety remains an important concern. Therefore, current research aims to discover compounds that combine:

High COX-2 inhibitory potency
↓
High COX-2/COX-1 selectivity
↓
Good anti-inflammatory activity
↓
Reduced gastrointestinal toxicity
↓
Lower cardiovascular risk
↓
Appropriate physicochemical properties
↓
Good metabolic and pharmacokinetic characteristics

The diversity of chemical scaffolds is particularly important because small structural changes can substantially modify COX-2 potency and selectivity. [3,6]

4. Scaffold-Based Design of COX-2 Inhibitors

A scaffold is the central structural framework of a molecule onto which different substituents can be introduced to optimize biological activity.

Scaffold-based synthesis involves:

Selection of suitable core scaffold
↓
Introduction of COX-2 pharmacophoric groups
↓
Structural modification at different positions
↓
Synthesis of analogue series
↓
Characterization
↓
In-vitro COX-1/COX-2 evaluation
↓
SAR analysis and molecular docking

Previous research has demonstrated that both classical diaryl heterocycles and non-diaryl scaffolds can provide selective COX-2 inhibitors. [3,6]

5. Important Scaffolds Investigated for COX-2 Inhibition

5.1 Pyrazole Scaffold

Pyrazole is one of the most important heterocyclic scaffolds in COX-2 inhibitor research. Celecoxib itself contains a diaryl pyrazole framework.

Substitution of the pyrazole ring with suitable aromatic groups and polar substituents can produce compounds with increased COX-2 selectivity. Recent reviews continue to identify pyrazole as a promising scaffold for developing new COX-2 inhibitors.[7,8]

A recent study of novel pyrazole derivatives reported selective COX-2 inhibition, with several compounds showing submicromolar inhibitory activity and additional anticancer properties.[9]

5.2 Indole Scaffold

Indole is another privileged scaffold investigated for COX-2 inhibition.

↓

Indole derivatives can be modified at different positions to introduce.

↓

Aromatic substituents

↓

Halogens

↓

Sulfonamide/sulfone groups

↓

Alkyl groups

↓

Heterocyclic substituents

A 2024 review covering indole-based COX-2 inhibitors reported substantial research activity during 2013–2024 and highlighted the versatility of the indole scaffold for SAR optimization.[10]

5.3 Pyridazine Scaffold

Pyridazine-containing compounds have attracted attention because suitable substitution around the heteroaromatic ring can provide potent COX-2 inhibitory activity.

A 2023 review described pyridazine as a promising scaffold and summarized synthetic approaches and SAR findings associated with pyridazine-based COX-2 inhibitors.[11]

5.4 1,2,4-Triazole Scaffold

Triazole-containing molecules are also useful in scaffold-based COX inhibitor development.

A 2024 study investigated substituted 1,2,4-triazoles bearing a tetrahydroisoquinoline scaffold as COX1/COX-2 inhibitors. Some compounds demonstrated favourable anti-inflammatory activity and gastric safety characteristics in experimental evaluation.[12]

5.5 Xanthone Scaffold

Xanthone represents a different structural framework for COX-2 inhibitor development. Researchers have used QSAR, molecular modelling and synthesis to investigate substituted xanthone derivatives.

This approach illustrates how computational drug design can be combined with scaffold modification and experimental evaluation to identify promising COX-2 selective candidates.[13]

6. Structure–Activity Relationship (SAR)

SAR is an important component of medicinal chemistry because it establishes the relationship between structural modifications and biological activity.

Important SAR observations reported for COX-2 inhibitors include:

6.1 Aromatic rings

Hydrophobic aromatic rings can occupy hydrophobic regions of the COX-2 binding site and contribute to binding affinity.

6.2 Sulfonamide/Sulfone group

A sulfonamide or sulfone-containing group is present in several classical COX-2 inhibitors and can contribute to selective interactions within the COX-2 active site.[3,5]

6.3 Halogen substitution

Halogen substituents such as fluorine and chlorine can modify lipophilicity, electronic characteristics and binding interactions.

For example, studies of substituted diaryl compounds have shown that the position and nature of substituents can strongly influence COX-2 potency and selectivity.[14]

6.4 Heterocyclic substitution

Heterocycles such as pyrazole, indole, pyridazine, pyridine, oxazole and pyrrole have been investigated extensively as central scaffolds or substituents.[6,8]

6.5 Spacer modification

The distance between aromatic groups and the central scaffold can influence the orientation of the molecule inside the COX-2 binding site. Studies have demonstrated that changing the spacer group can significantly affect potency and selectivity.[14]

7. Synthetic

The synthesis of novel COX-2 inhibitors generally involves the preparation of a central scaffold followed by functionalization with selected aromatic, heteroaromatic or polar groups.

A general research workflow can be represented as:

Starting material

↓
Formation of central heterocyclic scaffold
↓
Functional-group modification
↓
Aromatic/heteroaromatic substitution
↓
Purification
↓
Structural characterization
↓
Biological evaluation

Depending on the scaffold, reactions such as condensation, cyclization, substitution, coupling and acylation may be used.

For example, recent research has demonstrated synthesis of novel COX-2 inhibitor series based on pyrazole, pyrimidine, triazole, indole and other heterocyclic frameworks.[9,13]

8. Molecular Docking in COX-2 Inhibitor Design

Molecular docking is frequently used as a complementary tool in modern COX-2 drug discovery.

The general workflow is:

Novel scaffold design
↓
3D structure generation
↓
COX-2 protein preparation
↓
Molecular docking
↓
Binding-score analysis
↓
Interaction analysis
↓
Selection of promising compounds for synthesis

Docking can provide information about possible hydrogen bonds, hydrophobic interactions and other interactions between a candidate molecule and the COX-2 binding site.

However, docking results should be considered predictive, and biological assays are required to confirm actual inhibitory activity.

Recent COX-2 studies have combined synthesis, biological testing and molecular docking to support the optimization of novel scaffolds.[9,12,13]

9. Recent Research Developments

Recent literature demonstrates continued interest in developing new COX-2 inhibitors with structurally diverse scaffolds.

A 2023 review specifically highlighted the importance of scaffold diversity in next-generation COX-2 inhibitor development. The authors emphasized that exploring different chemical frameworks may help address limitations associated with existing COX-2 inhibitors.[6]

Recent work has also investigated:

Pyrazole derivatives [7,9] Indole derivatives [10]
Pyridazine derivatives[11]
Triazole derivatives[12]
Xanthone derivatives[13]
Pyrimidine derivatives[15]
Fenamate/ibuprofen-derived structures [16]
Hybrid heterocyclic compounds[17]

For example, a 2024 study involving fenamate and ibuprofen-derived compounds reported several potent selective COX-2 inhibitors and combined biological evaluation with computational studies.[16]

10. Research Gap

From the available literature, several important research gaps can be identified:

1. Many classical COX-2 inhibitors are based on well-established diaryl heterocyclic scaffolds.
2. Cardiovascular safety remains an important concern with highly selective COX-2 inhibition.
3. There is a continuing need for structurally diverse scaffolds with improved COX-2/COX-1 selectivity.

4. Small structural modifications can significantly alter potency, selectivity and safety.
5. More systematic integration of scaffold modification + SAR + molecular docking + biological evaluation is desirable.
6. Novel heterocyclic and hybrid scaffolds remain an active area of investigation.[3,6,10]

Proposed research gap for your B.Pharm project

"The existing literature demonstrates extensive exploration of classical diaryl and heterocyclic COX-2 inhibitor scaffolds; however, there remains a need to investigate structurally novel scaffold-based derivatives designed to improve COX-2 selectivity while maintaining favourable pharmacological and safety profiles."

This is a reasonable literature-based research gap, but it should be narrowed further after selecting the exact scaffold you intend to synthesize

11. Proposed Research Strategy

For your project, the following approach would be suitable:

Step 1 – Scaffold selection

↓

Select a chemically feasible heterocyclic scaffold based on literature SAR.

↓

Step 2 – Rational modification

↓

Introduce substituents expected to favour COX-2 binding.

↓

Step 3 – Design of derivatives

Prepare a small analogue series by varying substituents such as:

H, CH_3 ,OCH_3 ,F, Cl , Br ,NO_2

Step 4 – In-silico study

Perform molecular docking against COX-2 and compare binding interactions.

Step 5 – Synthesis

Synthesize the selected derivatives using an appropriate organic synthetic route.

Step 6 – Characterization

Characterize synthesized compounds using appropriate techniques such as:

Melting point

↓

TLC

↓

FT-IR

↓

^{1}H NMR

↓

^{13}C NMR

↓

Mass spectroscopy, where available

Step 7 – Biological evaluation

Evaluate COX-2 inhibitory activity and, where feasible, compare COX-1 activity to determine selectivity. **Step 8 – SAR correlation**

Correlate substituent changes with biological activity and docking results.

12. Conclusion

COX-2 remains an important molecular target for the development of anti-inflammatory agents. The discovery of selective COX-2 inhibitors represented an important advancement over conventional nonselective NSAIDs; however, cardiovascular safety concerns have stimulated continued research into new chemical entities. Scaffold-based drug design provides an effective strategy for generating structural diversity and optimizing potency and selectivity.

Literature studies demonstrate that pyrazole, indole, pyridazine, triazole, xanthone, pyrimidine and other heterocyclic frameworks can serve as useful scaffolds for COX-2 inhibitor development. Modern approaches combining rational scaffold design, SAR, molecular docking, chemical synthesis and biological evaluation can help identify promising novel COX-2 inhibitor candidates.[6,13]

Therefore, the proposed project "Design and Synthesis of Novel COX-2 Selective Inhibitor Candidates Using Scaffold-Based Synthesis" has a suitable medicinal-chemistry basis for further investigation.

References

1. Zarghi A, Arfaei S. Selective COX-2 inhibitors: A review of their structure-activity relationships. Iran J Pharm Res. 2011;10(4):655–683. PMID: 24250402.

2. Kalgutkar AS, Zhao Z. Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents. Curr Med Chem. 2001. doi:10.2174/1389450013348830.
3. Carullo G, Galligano F, Aiello F. Structure–activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009–2016). MedChemComm. 2017;8(3):492–500. doi:10.1039/C6MD00569A.
4. Patrignani P, Tacconelli S, Bruno A, et al. Update on COX-2 selective inhibitors: chemical classification, side effects and their use in cancers and neuronal diseases. Curr Med Chem. 2017.
5. Dannhardt G, Kiefer W. Structural approaches to explain the selectivity of COX-2 inhibitors: is there a common pharmacophore? Curr Med Chem. 2000. doi:10.2174/0929867003374237.
6. Design and Development of COX-II Inhibitors: Current Scenario and Future Perspective. 2023. This review emphasizes scaffold diversity as an important strategy for next-generation COX-2 inhibitor development.
7. Review of the recent advances of pyrazole derivatives as selective COX-2 inhibitors for treating inflammation. 2024.
8. Recent advancement in the discovery and development of COX-2 inhibitors: Insight into biological activities and SAR studies (2008–2019). 2019.
9. Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: Design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR/Topo-1 inhibition. 2022.
10. Shah M, Parmar R, Patel K, Nagani A. Indole-based COX-2 inhibitors: A decade of advances in inflammation, cancer, and Alzheimer's therapy. Bioorg Chem. 2024;153:107931. doi:10.1016/j.bioorg.2024.107931.
11. Ewieda SY, Ahmed EM, Hassan RA, Hassan MSA. Pyridazine derivatives as selective COX-2 inhibitors: A review on recent updates. Drug Dev Res. 2023. doi:10.1002/ddr.22118.
12. Abo-Elmagd MI, Hassan RM, Aboutabl ME, et al. Design, synthesis and anti-inflammatory assessment of certain substituted 1,2,4-triazoles bearing tetrahydroisoquinoline scaffold as COX 1/2-inhibitors. Bioorg Chem. 2024;150:107577. doi:10.1016/j.bioorg.2024.107577.
13. Saikia R, Pathak K, Das A, et al. Design, QSAR methodology, synthesis and assessment of some structurally different xanthone derivatives as selective COX-2 inhibitors for their anti-inflammatory properties. Med Chem. 2024;20(1):78–91. doi:10.2174/1573406419666230818092253.
14. Khanapure SP, Garvey DS, Young DV, et al. Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 selective inhibitors. J Med Chem. 2003;46(25):5484–5504. doi:10.1021/jm030268b.
15. Al-Ghulikah HA, El-Sebaey SA, Bass AKA, El-Zoghbi MS. New pyrimidine-5-carbonitriles as COX-2 inhibitors: Design, synthesis, anticancer screening, molecular docking, and in silico ADME profile studies. Molecules. 2022;27(21):7485. doi:10.3390/molecules27217485.
16. Elgohary MK, Elkotamy M, Alkabbani MA, Abdel-Aziz HA. Fenamates and ibuprofen as foundational components in the synthesis of innovative, targeted COX-2 anti-inflammatory drugs. Bioorg Chem. 2024;147:107393. doi:10.1016/j.bioorg.2024.107393.
17. Elgohary MK, et al. Fragment merging approach for the design of thiazole/thiazolidine clubbed pyrazoline derivatives as anti-inflammatory agents: synthesis, biopharmacological evaluation and molecular modeling studies. Bioorg Chem. 2023;106724. doi:10.1016/j.bioorg.2023.106724.

Copyright & License:

© Authors retain the copyright of this article. This work is published under the Creative Commons Attribution 4.0 International License (CC BY 4.0), permitting unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.